US 12,077,803 B2
MicroRNAs as biomarkers for endometriosis
Hugh Taylor, Easton, CT (US)
Assigned to Yale University, New Haven, CT (US)
Filed by YALE UNIVERSITY, New Haven, CT (US)
Filed on Nov. 2, 2021, as Appl. No. 17/517,014.
Application 17/517,014 is a continuation of application No. 17/184,894, filed on Feb. 25, 2021, granted, now 11,220,713.
Application 17/184,894 is a continuation of application No. 16/329,436, granted, now 10,982,282, previously published as PCT/US2017/049284, filed on Aug. 30, 2017.
Claims priority of provisional application 62/381,130, filed on Aug. 30, 2016.
Prior Publication US 2022/0049312 A1, Feb. 17, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C12Q 1/6883 (2018.01); G01N 33/53 (2006.01); G01N 33/68 (2006.01)
CPC C12Q 1/6883 (2013.01) [G01N 33/5308 (2013.01); G01N 33/689 (2013.01); C12Q 2600/112 (2013.01); C12Q 2600/158 (2013.01); C12Q 2600/178 (2013.01); G01N 2800/364 (2013.01)] 16 Claims
 
1. A method of treating endometriosis in a subject, the method comprising:
(I) determining that the subject has endometriosis by:
(a) providing a blood, serum, or plasma sample comprising nucleic acids from the subject;
(b) obtaining a detected level of at least one miRNA, wherein the level of the at least one miRNA is determined by performing an amplification reaction on at least one miRNA selected from the group consisting of: miR-125b, miR143, miR-145, miR-150, miR-342, miR-451, miR-3613, miR-500, miR-18, miR-214, miR-126, miR-553, miR-4668, and miR-6755;
(c) detecting endometriosis in the subject based on the level of the at least one miRNA; and
(II) administering a treatment for the endometriosis to the subject, thereby treating the endometriosis.